Contract research organization MedPharm has announced the opening of a new GLP laboratory at its Guildford, UK headquarters. According to the company, “The additional space will provide further capacity for MedPharm’s proprietary in vitro/ex vivo performance and equivalence testing models for topical, ophthalmic, nail, nasal and inhaled drugs/medical devices which continue to see growing demand from its clients on all continents.”
MedPharm CEO Andrew Muddle noted “All of these developments have combined to create a major increase in demand for our highly specialized services. At the moment I would say we are among the world leaders in performance testing in topical formulation development. However, we don’t intend to stand still and are therefore now opening these new state of the art facilities in Guildford to increase our performance testing capacity.”
The company, whose services include formulation development for nasal sprays and both MDIs and DPIs, says that it invested three quarters of a million dollars in the new lab.
